The Magnum Ice Cream Company N.V.

(TMICC or the Company)

Annual General Meeting – Update Statement – Resolution 5 Voting Outcome

The Company provides this update statement on its engagement with shareholders following the Annual General Meeting (AGM) held on 7 May 2026. Whilst a clear majority of shareholders, 77.37%, voted in favour of Resolution 5 (Proposal to adopt the Foundation Plan for Growth); the UK Corporate Governance Code requires an update statement to be published where a resolution receives more than 20% of votes against.

The Board engaged extensively with shareholders and governance bodies as the Foundation Plan was developed, and continues to believe that it balances accountability, an ownership mindset, alignment with shareholder interests and long-term value creation. The Board also notes that it rightly carries downside risk for senior leaders from their direct co-investment. Through this detailed engagement, the Company developed a strong understanding of stakeholder views on the Foundation Plan and received support from a clear majority.

Following the AGM in May, the Board continued this process of engagement with shareholders and, taking into account this feedback, concluded that no further actions are necessary at this time.

The Board would like to thank all the shareholders who have engaged with the Company for their continuing feedback and support.  In line with its normal practice, the Board will continue to engage with shareholders and their representative bodies and will provide further updates in the Company’s 2026 Annual Report.

Enquiries  
Media Relations
media.relations-tmicc@magnumicecream.com

Investor Relations
investor.relations-tmicc@magnumicecream.com

About The Magnum Ice Cream Company

The Magnum Ice Cream Company N.V. EURONEXT: MICC/ NYSE: MICC/ LSE: MICC is the world’s leading ice cream business. Home to four of the world’s five largest ice cream brands: Magnum, Ben & Jerry’s, Cornetto and the Heartbrand, our portfolio delights consumers in 80 markets around the world. Headquartered in Amsterdam, The Netherlands, we have a global team of 19,000 employees, a network of 32 factories, 13 R&D centres, and a fleet of three million freezer cabinets. For more information, visit www.corporate.magnumicecream.com. TMICC’s legal entity identifier is 25490052LLF3XH6G9847.

The Magnum Ice Cream Company N.V.

(TMICC or the Company)

Annual General Meeting – Update Statement – Resolution 5 Voting Outcome

The Company provides this update statement on its engagement with shareholders following the Annual General Meeting (AGM) held on 7 May 2026. Whilst a clear majority of shareholders, 77.37%, voted in favour of Resolution 5 (Proposal to adopt the Foundation Plan for Growth); the UK Corporate Governance Code requires an update statement to be published where a resolution receives more than 20% of votes against.

The Board engaged extensively with shareholders and governance bodies as the Foundation Plan was developed, and continues to believe that it balances accountability, an ownership mindset, alignment with shareholder interests and long-term value creation. The Board also notes that it rightly carries downside risk for senior leaders from their direct co-investment. Through this detailed engagement, the Company developed a strong understanding of stakeholder views on the Foundation Plan and received support from a clear majority.

Following the AGM in May, the Board continued this process of engagement with shareholders and, taking into account this feedback, concluded that no further actions are necessary at this time.

The Board would like to thank all the shareholders who have engaged with the Company for their continuing feedback and support.  In line with its normal practice, the Board will continue to engage with shareholders and their representative bodies and will provide further updates in the Company’s 2026 Annual Report.

Enquiries  
Media Relations
media.relations-tmicc@magnumicecream.com

Investor Relations
investor.relations-tmicc@magnumicecream.com

About The Magnum Ice Cream Company

The Magnum Ice Cream Company N.V. EURONEXT: MICC/ NYSE: MICC/ LSE: MICC is the world’s leading ice cream business. Home to four of the world’s five largest ice cream brands: Magnum, Ben & Jerry’s, Cornetto and the Heartbrand, our portfolio delights consumers in 80 markets around the world. Headquartered in Amsterdam, The Netherlands, we have a global team of 19,000 employees, a network of 32 factories, 13 R&D centres, and a fleet of three million freezer cabinets. For more information, visit www.corporate.magnumicecream.com. TMICC’s legal entity identifier is 25490052LLF3XH6G9847.

Yale physician-scientist and biotech entrepreneur Dr. Ranjit Bindra brings deep expertise in DNA repair, synthetic lethality and brain tumor therapeutics

VANCOUVER, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced the appointment of Dr. Ranjit Bindra, MD, PhD, to its Scientific Advisory Board (“SAB”). Dr. Bindra is the Scientific Director of the Yale Brain Tumor Center and the Harvey and Kate Cushing Professor of Therapeutic Radiology at the Yale School of Medicine.

“Dr. Bindra is a leader in the discovery, development and application of cancer therapies in the DNA-damage response field, and his appointment comes at an important moment for our Company,” said Kim Oishi, Chief Executive Officer of Rakovina Therapeutics. “His laboratory has a track record of turning fundamental discoveries in DNA repair into biomarker-driven clinical trials, and he has founded multiple oncology companies, one of which was acquired by Merck in 2024. That combination of scientific depth and commercial execution is exactly what we want guiding our programs as we advance toward IND-enabling studies.”

Dr. Bindra’s research sits at the intersection of several areas central to Rakovina’s pipeline, including synthetic lethality in DNA repair-deficient tumors, the therapeutic application of PARP and ATR inhibition, and strategies designed to enable blood-brain barrier penetration. His group led the discovery that IDH1/2-mutant tumors harbor a profound DNA repair defect that renders them highly sensitive to PARP inhibitors, work published in Nature, Nature Genetics, and Science Translational Medicine, and he is lead co-principal investigator of a 35-site, NCI-sponsored Phase II trial evaluating the PARP inhibitor olaparib in IDH1/2-mutant solid tumors.

“The central problem in treating brain tumors is not that we lack good targets, it is that most of the drugs we would want to use never reach them,” said Dr. Bindra. “Rakovina is pursuing DNA repair vulnerabilities with AI-designed molecules built from the outset to cross the blood-brain barrier. The team presented in vivo data on that approach at AACR this year. I have spent my career trying to move DNA repair biology out of the laboratory and into trials for patients who have very few options, and I am glad to be joining this team as it advances these programs toward the clinic.”

Dr. Bindra joins existing Scientific Advisory Board members Dr. Dennis Brown, PhD (Chair), Prof. Petra Hamerlik, Prof. Artem Cherkasov, and Dr. Leonard Post, PhD, each of whom brings decades of drug discovery and development experience to their advisory roles.

“Ranjit’s expertise is highly complementary to the work our team is doing across all three of our programs,” said Dr. Mads Daugaard, President and Chief Scientific Officer of Rakovina Therapeutics. “He has published on the synergy between ATR inhibition and DNA-damaging agents, he treats brain tumor patients clinically, and he understands the delivery challenges that define this field. As we advance our brain-penetrant DDR inhibitor programs, having a clinician-scientist of his calibre in the room will sharpen how we prioritize and translate our science.”

About Prof. Ranjit Bindra, MD, PhD

Dr. Ranjit Bindra, MD, PhD is the Harvey and Kate Cushing Professor of Therapeutic Radiology at the Yale School of Medicine and Scientific Director of the Yale Brain Tumor Center. A physician-scientist and radiation oncologist, he treats adult and pediatric patients with primary brain tumors and brain metastases using advanced radiation and radiosurgery.

His research focuses on uncovering fundamental DNA repair vulnerabilities in cancer and translating these discoveries into new therapies. His laboratory discovered that IDH1/2-mutant cancers harbor a profound defect in DNA repair that creates a powerful therapeutic vulnerability to PARP inhibition, work published in Nature, Nature Genetics, and Science Translational Medicine that has helped reshape the understanding of DNA repair targeting in cancer. More recently, his group reported a new strategy to exploit DNA repair defects through targeted DNA modification, published in Science, opening new avenues for therapeutic development.

Dr. Bindra is also an active biotech entrepreneur and has founded multiple biotechnology companies based on discoveries from his laboratory, including Cybrexa Therapeutics, Alphina Therapeutics, and Modifi Biosciences. Under his leadership as interim CEO, Modifi Biosciences was acquired by Merck in 2024.

He received his undergraduate degree from Yale University and his MD and PhD from the Yale School of Medicine and completed his residency and postdoctoral research training at Memorial Sloan Kettering Cancer Center.

Corporate Update

The Company would also like to provide the following corporate updates:

  • SR&ED tax refund: The Company received a gross Scientific Research and Experimental Development (SR&ED) tax refund of $920,846.10, including interest. Administered by the Canada Revenue Agency, SR&ED is Canada’s largest federal program supporting business research and development, providing tax incentives to companies that carry out experimental development and applied research within Canada. Rakovina’s refund reflects the scale of the Company’s research activity, which pairs AI-driven molecular design with laboratory validation at the University of British Columbia and the Vancouver Prostate Centre to develop novel inhibitors of the DNA-damage response. The funds will support advancement of Rakovina’s pipeline, including in vivo ADME and efficacy testing for the kt-5000AI dual ATR/mTOR inhibitor program, continued AI-driven lead optimization through the Company’s collaboration with Variational AI, advancement of the kt-3000 LNP formulation program, and ongoing kt-2000AI compound development.
  • Stock option grants: The Company’s board of directors has approved the grant of an aggregate of 2,910,500 stock options (the “Options”) to certain consultants, employees, officers and directors of the Company pursuant to the Company’s Long Term Incentive Plan. Each Option is exercisable at a price of $0.20 per common share and expires on the fifth anniversary of the grant date. The Options vest as to one quarter of each award every three months following the grant date, becoming fully vested one year after the grant date.

About Rakovina Therapeutics Inc.

Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using validated, proprietary platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before.

The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at www.rakovinatherapeutics.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

For Further Information Contact:

Kim Oishi
CEO
Kim.oishi@rakovinatherapeutics.com

Mark Mitchell
Director, IR & Communications
IR@rakovinatherapeutics.com

Notice Regarding Rakovina Therapeutics Forward-Looking Statements:

This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans,” “is expected,” “expects,” “scheduled,” “intends,” “contemplates,” “anticipates,” “believes,” “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may,” “could,” “would,” “might,” or “will” be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the biopharmaceutical industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition.

Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company’s most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company’s profile page at www.sedar.com.

Yale physician-scientist and biotech entrepreneur Dr. Ranjit Bindra brings deep expertise in DNA repair, synthetic lethality and brain tumor therapeutics

VANCOUVER, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced the appointment of Dr. Ranjit Bindra, MD, PhD, to its Scientific Advisory Board (“SAB”). Dr. Bindra is the Scientific Director of the Yale Brain Tumor Center and the Harvey and Kate Cushing Professor of Therapeutic Radiology at the Yale School of Medicine.

“Dr. Bindra is a leader in the discovery, development and application of cancer therapies in the DNA-damage response field, and his appointment comes at an important moment for our Company,” said Kim Oishi, Chief Executive Officer of Rakovina Therapeutics. “His laboratory has a track record of turning fundamental discoveries in DNA repair into biomarker-driven clinical trials, and he has founded multiple oncology companies, one of which was acquired by Merck in 2024. That combination of scientific depth and commercial execution is exactly what we want guiding our programs as we advance toward IND-enabling studies.”

Dr. Bindra’s research sits at the intersection of several areas central to Rakovina’s pipeline, including synthetic lethality in DNA repair-deficient tumors, the therapeutic application of PARP and ATR inhibition, and strategies designed to enable blood-brain barrier penetration. His group led the discovery that IDH1/2-mutant tumors harbor a profound DNA repair defect that renders them highly sensitive to PARP inhibitors, work published in Nature, Nature Genetics, and Science Translational Medicine, and he is lead co-principal investigator of a 35-site, NCI-sponsored Phase II trial evaluating the PARP inhibitor olaparib in IDH1/2-mutant solid tumors.

“The central problem in treating brain tumors is not that we lack good targets, it is that most of the drugs we would want to use never reach them,” said Dr. Bindra. “Rakovina is pursuing DNA repair vulnerabilities with AI-designed molecules built from the outset to cross the blood-brain barrier. The team presented in vivo data on that approach at AACR this year. I have spent my career trying to move DNA repair biology out of the laboratory and into trials for patients who have very few options, and I am glad to be joining this team as it advances these programs toward the clinic.”

Dr. Bindra joins existing Scientific Advisory Board members Dr. Dennis Brown, PhD (Chair), Prof. Petra Hamerlik, Prof. Artem Cherkasov, and Dr. Leonard Post, PhD, each of whom brings decades of drug discovery and development experience to their advisory roles.

“Ranjit’s expertise is highly complementary to the work our team is doing across all three of our programs,” said Dr. Mads Daugaard, President and Chief Scientific Officer of Rakovina Therapeutics. “He has published on the synergy between ATR inhibition and DNA-damaging agents, he treats brain tumor patients clinically, and he understands the delivery challenges that define this field. As we advance our brain-penetrant DDR inhibitor programs, having a clinician-scientist of his calibre in the room will sharpen how we prioritize and translate our science.”

About Prof. Ranjit Bindra, MD, PhD

Dr. Ranjit Bindra, MD, PhD is the Harvey and Kate Cushing Professor of Therapeutic Radiology at the Yale School of Medicine and Scientific Director of the Yale Brain Tumor Center. A physician-scientist and radiation oncologist, he treats adult and pediatric patients with primary brain tumors and brain metastases using advanced radiation and radiosurgery.

His research focuses on uncovering fundamental DNA repair vulnerabilities in cancer and translating these discoveries into new therapies. His laboratory discovered that IDH1/2-mutant cancers harbor a profound defect in DNA repair that creates a powerful therapeutic vulnerability to PARP inhibition, work published in Nature, Nature Genetics, and Science Translational Medicine that has helped reshape the understanding of DNA repair targeting in cancer. More recently, his group reported a new strategy to exploit DNA repair defects through targeted DNA modification, published in Science, opening new avenues for therapeutic development.

Dr. Bindra is also an active biotech entrepreneur and has founded multiple biotechnology companies based on discoveries from his laboratory, including Cybrexa Therapeutics, Alphina Therapeutics, and Modifi Biosciences. Under his leadership as interim CEO, Modifi Biosciences was acquired by Merck in 2024.

He received his undergraduate degree from Yale University and his MD and PhD from the Yale School of Medicine and completed his residency and postdoctoral research training at Memorial Sloan Kettering Cancer Center.

Corporate Update

The Company would also like to provide the following corporate updates:

  • SR&ED tax refund: The Company received a gross Scientific Research and Experimental Development (SR&ED) tax refund of $920,846.10, including interest. Administered by the Canada Revenue Agency, SR&ED is Canada’s largest federal program supporting business research and development, providing tax incentives to companies that carry out experimental development and applied research within Canada. Rakovina’s refund reflects the scale of the Company’s research activity, which pairs AI-driven molecular design with laboratory validation at the University of British Columbia and the Vancouver Prostate Centre to develop novel inhibitors of the DNA-damage response. The funds will support advancement of Rakovina’s pipeline, including in vivo ADME and efficacy testing for the kt-5000AI dual ATR/mTOR inhibitor program, continued AI-driven lead optimization through the Company’s collaboration with Variational AI, advancement of the kt-3000 LNP formulation program, and ongoing kt-2000AI compound development.
  • Stock option grants: The Company’s board of directors has approved the grant of an aggregate of 2,910,500 stock options (the “Options”) to certain consultants, employees, officers and directors of the Company pursuant to the Company’s Long Term Incentive Plan. Each Option is exercisable at a price of $0.20 per common share and expires on the fifth anniversary of the grant date. The Options vest as to one quarter of each award every three months following the grant date, becoming fully vested one year after the grant date.

About Rakovina Therapeutics Inc.

Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using validated, proprietary platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before.

The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at www.rakovinatherapeutics.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

For Further Information Contact:

Kim Oishi
CEO
Kim.oishi@rakovinatherapeutics.com

Mark Mitchell
Director, IR & Communications
IR@rakovinatherapeutics.com

Notice Regarding Rakovina Therapeutics Forward-Looking Statements:

This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans,” “is expected,” “expects,” “scheduled,” “intends,” “contemplates,” “anticipates,” “believes,” “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may,” “could,” “would,” “might,” or “will” be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the biopharmaceutical industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition.

Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company’s most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company’s profile page at www.sedar.com.

LONDON, Sept. 17, 2026 (GLOBE NEWSWIRE) — Sompo International Holdings Ltd. today announced that Nicolas (Nic) Berg is appointed CEO of Sompo’s UK Insurance business, effective October 1, 2026, subject to regulatory approval. Mr Berg joins Sompo from SCOR Group where he was most recently CEO of SCOR US and Head of P&C North America.

Mr Berg succeeds Sarah Stanford who has led the UK Insurance business through its initial integration period following Sompo’s acquisition of Aspen. Ms Stanford is stepping down as CEO, UK Insurance on September 30.

Mr Berg will be based in London and will report to Alessa Quane, CEO of International Markets.

A highly experienced CEO, Mr. Berg spent much of his 25-year career at AIG in a succession of global and regional executive roles focused on the UK and European markets. Based in London, he served as Head of Liability and Financial Lines for the UK, Lloyd’s and EMEA, sat on the AIG Europe Ltd (UK) Executive Committee and chaired its Insurance Risk Committee. Mr. Berg has also led claims at scale, including as AIG Chief Claims Officer for North America.

Ms Quane said: “As an established insurance executive with deep industry knowledge and significant UK and global market experience, Nic brings a dynamic and forward-looking approach to leadership. He will play a critical role in advancing our strategy, accelerating our momentum and positioning Sompo as a leading commercial insurer in the UK market. I thank Sarah for her contributions and commitment and wish her all the best for the future.”

About Sompo 

We are Sompo, a global provider of commercial and consumer property, casualty, and specialty insurance and reinsurance. Building on the 138 years of innovation of our parent company, Sompo Holdings, Inc., Sompo employs approximately 10,000 people around the world who use their in-depth knowledge and expertise to help simplify and resolve your complex challenges. Because when you choose Sompo, you choose The Ease of Expertise™. 

“Sompo” refers to the brand under which Sompo International Holdings Ltd., a Bermuda-based holding company, together with its consolidated subsidiaries, operates its global property and casualty (re)insurance businesses. Sompo International Holdings Ltd. is an indirect wholly-owned subsidiary of Sompo Holdings, Inc., one of the leading property and casualty groups in the world with excellent financial strength as evidenced by ratings of A+ (Superior) from A.M. Best (XV size category) and A+ (Strong) from Standard & Poor’s. Shares of Sompo Holdings, Inc. are listed on the Tokyo Stock Exchange. 

To learn more please follow us on LinkedIn or visit sompo.com. 

Contact

Mike Jones
Global Head of Media Relations
M: +44 7765 901899
E: mijones@sompo-intl.com

LONDON, Sept. 17, 2026 (GLOBE NEWSWIRE) — Sompo International Holdings Ltd. today announced that Nicolas (Nic) Berg is appointed CEO of Sompo’s UK Insurance business, effective October 1, 2026, subject to regulatory approval. Mr Berg joins Sompo from SCOR Group where he was most recently CEO of SCOR US and Head of P&C North America.

Mr Berg succeeds Sarah Stanford who has led the UK Insurance business through its initial integration period following Sompo’s acquisition of Aspen. Ms Stanford is stepping down as CEO, UK Insurance on September 30.

Mr Berg will be based in London and will report to Alessa Quane, CEO of International Markets.

A highly experienced CEO, Mr. Berg spent much of his 25-year career at AIG in a succession of global and regional executive roles focused on the UK and European markets. Based in London, he served as Head of Liability and Financial Lines for the UK, Lloyd’s and EMEA, sat on the AIG Europe Ltd (UK) Executive Committee and chaired its Insurance Risk Committee. Mr. Berg has also led claims at scale, including as AIG Chief Claims Officer for North America.

Ms Quane said: “As an established insurance executive with deep industry knowledge and significant UK and global market experience, Nic brings a dynamic and forward-looking approach to leadership. He will play a critical role in advancing our strategy, accelerating our momentum and positioning Sompo as a leading commercial insurer in the UK market. I thank Sarah for her contributions and commitment and wish her all the best for the future.”

About Sompo 

We are Sompo, a global provider of commercial and consumer property, casualty, and specialty insurance and reinsurance. Building on the 138 years of innovation of our parent company, Sompo Holdings, Inc., Sompo employs approximately 10,000 people around the world who use their in-depth knowledge and expertise to help simplify and resolve your complex challenges. Because when you choose Sompo, you choose The Ease of Expertise™. 

“Sompo” refers to the brand under which Sompo International Holdings Ltd., a Bermuda-based holding company, together with its consolidated subsidiaries, operates its global property and casualty (re)insurance businesses. Sompo International Holdings Ltd. is an indirect wholly-owned subsidiary of Sompo Holdings, Inc., one of the leading property and casualty groups in the world with excellent financial strength as evidenced by ratings of A+ (Superior) from A.M. Best (XV size category) and A+ (Strong) from Standard & Poor’s. Shares of Sompo Holdings, Inc. are listed on the Tokyo Stock Exchange. 

To learn more please follow us on LinkedIn or visit sompo.com. 

Contact

Mike Jones
Global Head of Media Relations
M: +44 7765 901899
E: mijones@sompo-intl.com

FORM 8.5 (EPT/RI)

Amendment in 1(b)
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader: Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Tribal Group Plc
(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Advisor and Joint Broker to Tribal Group Plc
(d)        Date dealing undertaken: 16th September 2026

(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?
        If it is a cash offer or possible cash offer, state “N/A”
N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchases/ sales

Total number of securities Highest price per unit paid/received Lowest price per unit paid/received

Ordinary shares

Purchase

200,000

81.2 81.2

Ordinary shares

Sales

201,390

81.4 81.2

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
N/A N/A N/A N/A N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit
N/A N/A N/A N/A N/A N/A N/A N/A

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit
N/A N/A N/A N/A N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)
N/A N/A N/A N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i)        the voting rights of any relevant securities under any option; or
(ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure: 17th September 2026
Contact name: Priyali Bhattacharjee
Telephone number: +91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

FORM 8.5 (EPT/RI)

Amendment in 1(b)
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader: Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Tribal Group Plc
(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Advisor and Joint Broker to Tribal Group Plc
(d)        Date dealing undertaken: 16th September 2026

(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?
        If it is a cash offer or possible cash offer, state “N/A”
N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchases/ sales

Total number of securities Highest price per unit paid/received Lowest price per unit paid/received

Ordinary shares

Purchase

200,000

81.2 81.2

Ordinary shares

Sales

201,390

81.4 81.2

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
N/A N/A N/A N/A N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit
N/A N/A N/A N/A N/A N/A N/A N/A

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit
N/A N/A N/A N/A N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)
N/A N/A N/A N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i)        the voting rights of any relevant securities under any option; or
(ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure: 17th September 2026
Contact name: Priyali Bhattacharjee
Telephone number: +91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

Octopus AIM VCT plc

Net Asset Value

Octopus AIM VCT plc announces that as at 14 September 2026 the unaudited net asset value of the Ordinary shares was approximately 39.9 pence per share.

For further information, please contact:

Ronan Goggin
Octopus Company Secretarial Services Limited
Tel: +44 (0)80 0316 2067

LEI: 213800C5JHJUQLAFP619

Octopus AIM VCT plc

Net Asset Value

Octopus AIM VCT plc announces that as at 14 September 2026 the unaudited net asset value of the Ordinary shares was approximately 39.9 pence per share.

For further information, please contact:

Ronan Goggin
Octopus Company Secretarial Services Limited
Tel: +44 (0)80 0316 2067

LEI: 213800C5JHJUQLAFP619

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.